New drug BL-B01D1 shows promise for Hard-to-Treat cancers
NCT ID NCT05262491
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called BL-B01D1 in people with advanced stomach or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any side effects. About 96 adults aged 18 to 75 will take part, and researchers will also look for early signs that the drug is shrinking tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100037, China
-
Jinan Central Hospital
RECRUITINGJinan, Shandong, China
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, China
-
Tianjin Medical University General Hospital
RECRUITINGTianjin, Tianjin Municipality, China
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody drug targets Hard-to-Treat cancers
- New hope for Hard-to-Treat breast cancer: phase 3 trial launches
- New drug aims to stop Chemo-Induced bleeding risk in stomach and colon cancers
- New stem cell transplant shows promise for kids with tough cancers
- New hope for kids with rare cancers: brigatinib trial opens
- New combo aims to shield bone marrow in tough breast cancer